AlgoTherapeutix Completes Phase I for Peripheral Neuropathy Program ATX01, Poised for Phase II Initiation in 2022
17.11.2021 12:02:00 EET | Business Wire | Press release
France-based biotechnology company AlgoTherapeutix, developer of ATX01, an innovative topical treatment for the pain of peripheral neuropathy, announced today that the ATX01 Phase I trial successfully reached its safety and pharmacokinetics objectives, clearing the way for Phase II development in Chemotherapy-Induced Peripheral Neuropathy (CIPN).
Stéphane Thiroloix, Founder & CEO of AlgoTherapeutix, comments : “The outcome of this Phase I trial is an important milestone for AlgoTherapeutix. We are delighted that ATX01’s innovative approach and formulation did not raise any safety concern, and its PK profile is consistent with our objectives. We are now busy preparing for the pivotal Phase II CIPN study.”
Over half of cancer patients treated with chemotherapy - over two million patients in the US and Europe - develop CIPN and experience sensory symptoms and pain in the feet and hands: loss of sensitivity, tingling, burning, cold and intense pain can persist for months to years after treatment. CIPN is a leading cause of modification or interruption of chemotherapy. To this date, no therapeutic approach has offered a satisfactory response for patients and their caregivers, oncologists and pain specialists.
A recent publication in the “Journal of Pain” describes the exploratory pharmacological impact of high-dose topical amitriptyline in CIPN patients along with the mechanism of action supporting its activity (https://doi.org/10.1016/j.jpain.2020.11.002)
About AlgoTherapeutix : AlgoTherapeutix is a French biotech founded in 2018 to develop innovative solutions for complex pain. In 2020, AlgoTherapeutix raised a 12 M€ Series A led by Bpifrance and Omnes Capital to move its lead program ATX01 into clinical development. ATX01 is Phase II ready in painful peripheral neuropathy.
More information on AlgoTherapeutix : www.algotx.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211117005624/en/
Contact information
Contact AlgoTherapeutix :
AlgoTherapeutix SAS
49 rue des Nouvelles - 92150 Suresnes
contact@algotx.com
Press contact :
Geneviève Cliquet Consultant
T: +33(0) 607 500 567
contact@cliquet-consultant.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Reply Selected by Microsoft as Launch Partner for Agent 365, Supporting the Governance and Scaling of AI agents8.4.2026 11:17:00 EEST | Press release
Reply [EXM, STAR: REY] has been confirmed one of a small number of Launch Partners for Agent 365, supporting the general availability of Microsoft's new platform designed to provide enterprise-grade governance, observability and lifecycle management for AI agents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260408212380/en/ Through this collaboration with Microsoft, Reply reinforces its commitment to enabling organisations to implement artificial intelligence responsibly and at scale, supporting long-term digital transformation objectives. Microsoft Agent 365 introduces a structured framework enabling organisations to deploy, monitor and manage AI agents consistently across business functions. As artificial intelligence becomes embedded in core operational processes, Agent 365 provides clarity, control and accountability, ensuring that AI-driven activities remain transparent, secure and aligned with organisational objecti
HPE Takes Licence to Patents Offered Through the Sisvel Wi-Fi Multimode Pool8.4.2026 11:00:00 EEST | Press release
Hewlett Packard Enterprise (HPE) has become the latest company to take a licence to the patents offered through the recently launched Sisvel Wi-Fi Multimode pool. It joins Sony Group Corporation, Huawei, Panasonic, Philips and ZTE as a licensee of the programme. The latter four are also licensors, along with KPN, Mitsubishi Electric, Orange, Aegis 11 SA (a Sisvel affiliate), SK Telecom and Wilus. HPE is a major presence in the global WLAN market and is a leading manufacturer of both consumer and enterprise routers. The deal with Sisvel was reached on an amicable basis. The Sisvel Wi-Fi Multimode pool is the successor programme to the Sisvel Wi-Fi 6 patent pool. Over a three-year period, this closed agreements with nearly 40 companies, including Acer, Netgear, Cisco and HP. Covering Wi-Fi 7 as well as 6, the Multimode programme offers an efficient way to access essential Wi-Fi rights for years to come. “We are delighted to welcome Hewlett Packard Enterprise as the latest licensee of the
Zyxel and Openreach Team Up to Reduce Plastic Waste in Full Fibre Installations8.4.2026 11:00:00 EEST | Press release
A new partnership between Zyxel Communications and Openreach is helping to cut plastic and packaging waste from the UK’s Full Fibre rollout - by deploying re-cycled ‘modems’ to connect customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260408766604/en/ Openreach - GPON ONT Zyxel is deploying a range of new Optical Network Terminals (ONTs) - the wall-mounted box of electronics that converts optical signals into electrical ones used by household devices - with re-engineered casings made from 95 per cent recycled plastic.1 Openreach engineers have already installed half a million of Zyxel’s sustainable ONTs and the network provider expects to install even more this year as customers upgrade to Full Fibre - the UK’s most reliable broadband technology. The GPON2 devices use recycled plastic in their construction and arrive in zero‑plastic minimal packaging made from recycled materials. Openreach is working with Zyxel and o
Jeito Capital Hits Record $1.2 Billion (€1 Billion) 1 Close for Jeito II Fund to Drive Breakthrough Therapeutic Innovation for Patients8.4.2026 09:15:00 EEST | Press release
Jeito Capital (“Jeito”), a global independent private equity fund dedicated to Biopharma, today announces the final closing of its second fund Jeito II, exceeding its target at $1.2billion (above €1billion)1,2, and marking a new major milestone for European Biopharma investment. With this new fund, Jeito has now tripled its assets under management to €1.6 billion, following the closing in 2021 of fund Jeito I at $630 million (€534 million) and reinforces its position as a leading fully independent European Biopharma investor. Jeito II will continue the strategy established with Jeito I: selectively identifying and backing 15 to 20 of the most promising clinical stage Biopharma companies, primarily in Europe, developing breakthrough therapies for severe diseases with high unmet medical needs and accelerating the development path and future market access. This fundraising allows Jeito to increase the average size of future investments in portfolio companies up to €150 million, thus drivi
Croma-Pharma Acquires Synocrom™ and Returns to Orthopaedics8.4.2026 08:00:00 EEST | Press release
Croma-Pharma is returning to the orthopaedics market with the reacquisition of Synocrom™, a hyaluronic acid product for the treatment of knee osteoarthritis. A strategic return built on proven heritage With the reacquisition of Synocrom™, Croma-Pharma is re-entering orthopaedics and further broadening its portfolio in a field with strong historical roots for the company. Until 2014, Croma was active in orthopaedics, with Synocrom™ serving as a key pillar of its offering. Synocrom™ is not a new name in the market. During the period in which Croma actively marketed the product, it became one of the leading hyaluronic acid brands in Europe and ranked among the top brands in its category. Its return therefore represents more than a portfolio expansion: it marks the continuation of a successful orthopaedic legacy and reconnects Croma with an important part of its history. The reintroduction of Synocrom™ also builds on Croma-Pharma’s long-standing expertise in the development and manufacturi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom